Advocating for a world where intellectual
property law serves the public interest.

Addressing Exclusivity Issues During the COVID-19 Pandemic and Beyond

[Michael S. Sinha, Sven Bostyn, and Timo Minssen] Abstract: ... This chapter addresses exclusivity issues, with a particular emphasis on regulatory exclusivities for vaccines and therapeutics. We begin with a basic overview of the current regulatory exclusivity landscape in Europe and the US, followed by a discussion of current developments in COVID-19 vaccines and therapeutics. Next, we describe the influence
Read more

The Proposed TRIPS Waiver and Pharmaceutical Industry’s Concerns about Counterfeit COVID-19 Vaccines

[Muhammad Zaheer Abbas] Submission to the Australian Parliament’s Joint Committee on Law Enforcement Inquiry into Vaccine Related Fraud and Security Risks - Executive Summary: Australia needs to support the proposal of temporarily waiving intellectual property protections to scale up production and supply of vaccines and other COVID-19 related treatments and diagnostics. The Brand-name pharmaceutical industry’s claim that the proposed TRIPS
Read more

Interfaces and Interoperability After Google v. Oracle

[Mark A. Lemley and Pamela Samuelson] Abstract: We address an important issue the Supreme Court left unaddressed this spring in its blockbuster Google v. Oracle decision: are computer interfaces copyrightable at all? We argue that they aren’t, and that the Federal Circuit's decision to the contrary is an aberration that should not undermine a quarter century of consensus on the
Read more

The TRIPS COVID-19 Waiver, Challenges for Africa and Decolonizing Intellectual Property

[Yousuf Vawda] The intellectual property (IP) regimes of African countries are a function of their colonial past, which imposed strong protections, and which have been entrenched through the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement). This has had a devastating effect on their ability to access necessary health products both before and during the current COVID-19
Read more

New Book – Intellectual Property Law and Access to Medicines: TRIPS Agreement, Health and Pharmaceuticals

[Srividhya Ragavan] Amaka Vanni and I are pleased to share our new book, Intellectual Property Law and Access to Medicines: TRIPS Agreement, Health, and Pharmaceuticals. The book maps 25 years of TRIPS from the perspective of access to medication discourse by looking at three generations of access to medication debate.
Read more

The WTO TRIPS Waiver Should Help Build Vaccine Manufacturing Capacity in Africa

[Faizel Ismail] The current global health crisis created by the COVID-19 pandemic has re-focused our attention on the inadequacy of the TRIPS agreement and the patent system to address global public health crises. This time, developing countries must ensure that the TRIPS waiver succeeds in creating the impetus for the building of manufacturing capacity in the poorest countries, especially in
Read more

Posts by Category